Roche picks up a new autoimmune drug with $580M Adheron deal

10-9 – BWH spinout and PIF portfolio company, Adheron, has been acquired by Roch. Adheron is developing antibodies (currently in Phase I) targeting cadherin-11 for treatment of rheumatoid arthritis and other indications, and is based on technology developed by Michael Brenner, MD at BWH. Roche will be a great partner to move the product forward into Phase II trials and hopefully to market. The total deal value is $580 million, with $105 million paid on closing.
The initial payout will be approximately $5.2 million for PIF (for our $1.3 million investment) and $473K for BWH from the license (subject to patent policy splits). The total payout over time could reach $32 million for PIF and $5 million for BWH if all milestones are reached, with the next major milestone being a positive Phase II trial.

http://www.prnewswire.com/news-releases/adheron-therapeutics-to-be-acquired-by-roche-300156996.html

Most Recent Posts:

Blog MGB Implements DexCare image

Mass General Brigham Implements DexCare to Support Care Integration and Advance Digital Health

Collaboration demonstrates Mass General Brigham’s commitment to digital transformation and enhancing patient experience   SEATTLE, Oct. 31, 2022…

Read More
Blog Innovation Grand Rounds Khurana

Innovation Grand Rounds: Clinical Innovation in Trauma: From Inception to Automation to Impact

Innovation Grand Rounds is a monthly live series with talks by innovators and executives from across the…

Read More
Advamed

McKenna invited as panelist at Advamed MedTech Conference

Photo, left to right: Joseph Ferrara (moderator), Veranex Solutions; Philip Rackliffe, GE Healthcare; Erin McKenna; Kevin Boyle,…

Read More